REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
—————————
For the month of March 2006

Form 20-F x

Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o

No x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________

 

---

 

 

On March 21, 2006, sanofi-aventis issued the press release attached hereto as Exhibit 99.1 and the related Q&A document attached hereto as Exhibit 99.2, which are incorporated herein by reference.

 

	Exhibit Index
Exhibit No.	Description

Exhibit 99.1	Press Release dated March 21, 2006 announcing an agreement regarding the U.S. clopidogrel patent litigation.
Exhibit 99.2	Q&A document related to the press release included herein as Exhibit 99.1.

 

 

 

2

 

 

---

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: March 22, 2006	SANOFI-AVENTIS
	By:	/s/ Patricia Kodyra
		Name:	Patricia Kodyra
		Title:	Associate Vice President Financial and Securities Law

 

 

 

 

3

 

 

---

 

 

	Exhibit Index
Exhibit No.	Description
Exhibit 99.1	Press Release dated March 21, 2006 announcing an agreement regarding the U.S. clopidogrel patent litigation.
Exhibit 99.2	Q&A document related to the press release included herein as Exhibit 99.1.

 

 

 

 

4